- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05291806
Second Meal Effects of a Wholegrain Cereal Product on Blood Glucose Response
29. juni 2022 opdateret af: Aventure AB
The aim of this study is to investigate second meal effects of a wholegrain cereal product on blood glucose response.
The wholegrain cereal product will be consumed in the evening and blood glucose analyzed after a standardized breakfast meal the following morning.
Studieoversigt
Status
Afsluttet
Betingelser
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
17
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Lund, Sverige
- Aventure AB
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
35 år til 65 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Male or Female, 35 to 65 years of age
- BMI 18.5-29.9 kg/m2
- Agree to maintain consistent dietary habits and physical activity levels for the duration of the study.
- Healthy as determined by medical history and information provided by the volunteer.
- Willingness to complete questionnaires and follow instructions associated with the study and to complete all visits.
- Has given voluntary, written, informed consent to participate in the study.
Exclusion Criteria:
- Elevated fasting blood glucose (above 6.1 mmol/L at fasting on visit 1, 2, 3 or 4)
- Women who are pregnant or breast feeding
- Any medical condition(s) or medication(s) known to significantly affect glucose metabolism. Significance to be assessed by the QI
- Use of medication, over-the-counter medication, natural health products or dietary supplements/probiotics that may affect glucose metabolism is prohibited during this study. Significance to be assessed by the QI. Participants who are taking allowed prescribed medications must agree to maintain their current method and dosing regimen during the course of the study unless other is recommended by their physician.
- Known Type I or Type II diabetes, including women who previously have had gestational diabetes.
- Use of antibiotics within 2 weeks of enrollment
- Metabolic diseases and/or chronic gastrointestinal diseases (IBS, Crohns etc.)
- Allergy to ingredients included in investigational product, reference, or standardized meal
- Participants restricted to a vegetarian or vegan diet
- Intolerance to gluten
- Individuals who are averse to venous catheterization or capillary blood sampling
- Currently active smokers (or using other tobacco products, and e-cigarettes)
- Unstable medical conditions as determined by QI
- Participation in other clinical research trials
- Individuals who are cognitively impaired and/or who are unable to give informed consent
- Acute infection
Any other condition which in the QI's opinion may adversely affect the individual's ability to complete the study or its measures or which may pose significant risk to the individual
-
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Reference
|
This intervention is based on white rice.
|
|
Aktiv komparator: Whole cereal kernels Dose A
|
This wholegrain intervention contains whole cereal kernels.
|
|
Aktiv komparator: Whole cereal kernels Dose B
|
This wholegrain intervention contains whole cereal kernels.
|
|
Aktiv komparator: Cut cereal kernels Dose A
|
This wholegrain intervention contains cut cereal kernels.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Postprandial capillary blood glucose iAUC (0-120 min)
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in capillary blood glucose between wholegrain products and reference in the total incremental area under the curve iAUC(0-120 min) after the standardized breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Postprandial capillary blood glucose Cmax
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in capillary blood glucose between wholegrain products and reference in 2-hour Cmax(0-120 min) (maximum concentration) after the breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
|
Postprandial capillary blood glucose Tmax
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in capillary blood glucose between wholegrain products and reference in 2-hour Tmax(0-120 min) (the time to maximum concentration) after the breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
|
Fasting capillary blood glucose
Tidsramme: Outcome measures will be assessed just before the standardized meal is consumed.
|
The change in fasting capillary blood glucose the morning after consuming either wholegrain products or reference.
|
Outcome measures will be assessed just before the standardized meal is consumed.
|
|
Postprandial capillary blood glucose iAUC (0-60 min)
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in capillary blood glucose between wholegrain products and reference in the 1-hour incremental area under the curve iAUC(0-60 min) after the standardized breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
|
Postprandial capillary blood glucose 2-hour iPeak(0-120 min) (incremental maximum value)
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in capillary blood glucose between wholegrain products and reference in the 2-hour iPeak(0-120 min) (incremental maximum value) after the breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
|
Postprandial Insulin iAUC(0-120 min)
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in venous blood insulin between wholegrain products and reference in the total incremental area under the curve iAUC(0-120 min) after the standardized breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
|
Postprandial Insulin Cmax
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in venous blood insulin between wholegrain products and reference in Cmax after the standardized breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
|
Postprandial Insulin Tmax
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in venous blood insulin between wholegrain products and reference in Tmax after the standardized breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
|
Fasting Insulin
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in fasting venous blood insulin the morning after consuming either wholegrain products or reference.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
|
Postprandial insulin iAUC (0-60 min)
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in venous blood insulin between wholegrain products and reference in the 1-hour incremental area under the curve iAUC(0-60 min) after the standardized breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
|
Postprandial venous blood insulin 2-hour iPeak(0-120 min) (incremental maximum value)
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in venous blood insulin between wholegrain products and reference in the 2-hour iPeak(0-120 min) (incremental maximum value) after the breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Fasting GLP-1
Tidsramme: Outcome measures will be assessed just before the standardized meal is consumed.
|
The change in fasting GLP-1 the morning after consuming either wholegrain products or reference.
|
Outcome measures will be assessed just before the standardized meal is consumed.
|
|
GLP-1 iAUC(0-120 min)
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in GLP-1 between wholegrain products and reference in the total incremental area under the curve iAUC(0-120 min) after the standardized breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
|
GLP-1 iAUC(0-60 min)
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in GLP-1 between wholegrain products and reference in the1-hour incremental area under the curve iAUC(0-60 min) after the standardized breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
|
GLP-1 Cmax
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The changein GLP-1 between wholegrain products and reference in Cmax after the standardized breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
|
GLP-1 Tmax
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in GLP-1 between wholegrain products and reference in Tmax after the standardized breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
|
Fasting PYY
Tidsramme: Outcome measures will be assessed just before the standardized meal is consumed.
|
The change in fasting PYY the morning after consuming either wholegrain products or reference.
|
Outcome measures will be assessed just before the standardized meal is consumed.
|
|
PYY 2-hour mean concentration
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in PYY between the wholegrain products and the reference in the 2-hour mean concentration after the breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
|
PYY 1-hour mean concentration
Tidsramme: Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
The change in PYY between the wholegrain products and the reference in the 1-hour mean concentration after the breakfast meal.
|
Outcome measures will be assessed just before and immediately after the standardized meal is consumed.
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
17. marts 2022
Primær færdiggørelse (Faktiske)
13. juni 2022
Studieafslutning (Faktiske)
13. juni 2022
Datoer for studieregistrering
Først indsendt
14. marts 2022
Først indsendt, der opfyldte QC-kriterier
14. marts 2022
Først opslået (Faktiske)
23. marts 2022
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
5. juli 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
29. juni 2022
Sidst verificeret
1. marts 2022
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- TSP2201
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Ingen
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Blodglukoserespons
-
University of California, San DiegoAfsluttetHudtryk under Blood Draw-tourniquetsForenede Stater
-
Kasr El Aini HospitalAfsluttetRetained Blood Syndrome | Åben hjertekirurgi | BrystrørEgypten
-
John M. StulakAfsluttet
-
Assiut UniversityIkke rekrutterer endnuGyldigheden af Blood Pool SUV-ratio i identifikation af malignitet i tilfælde af syg lever
-
BioglaneUniversity Rovira i Virgili; National Research Council, Spain; Technological...AfsluttetInsulinemisk respons | Glykæmisk responsSpanien
-
PepsiCo Global R&DAfsluttetGlykæmisk respons | Insulinemisk respons | Emne Hunger ResponseCanada
-
PepsiCo Global R&DAfsluttetGlykæmisk respons | Insulinemisk respons | Subjectvie SultCanada
-
Azienda Ospedaliera Specializzata in Gastroenterologia...AfsluttetSunde emner | Glykæmisk respons | Insulinemisk responsItalien
-
Nutricia ResearchINQUIS Clinical ResearchAfsluttet
-
INQUIS Clinical ResearchUniversity of SaskatchewanAfsluttet
Kliniske forsøg med Reference Product
-
Radicle ScienceAfsluttetKognitiv funktionForenede Stater
-
Radicle ScienceAfsluttetSmerte | Neuropatisk smerte | Nociceptiv smerteForenede Stater
-
Radicle ScienceAfsluttet
-
Lumosa Therapeutics Co., Ltd.RekrutteringAkut iskæmisk slagtilfældeForenede Stater, Taiwan
-
M2 IngredientsRekrutteringKognitiv tilbagegangForenede Stater
-
Société des Produits Nestlé (SPN)University of NottinghamAfsluttetSund og raskDet Forenede Kongerige
-
Radicle ScienceAfsluttetKognitiv funktionForenede Stater
-
Radicle ScienceAfsluttetSeksuel funktion | Seksuel tilfredsstillelseForenede Stater
-
Radicle ScienceRekruttering